Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer.
Journal of Clinical Oncology.
Times cited: 168
Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target.
Times cited: 81
EGFR and K-ras mutation analysis in non-small cell lung cancer: Comparison of paraffin embedded versus frozen specimens.
Times cited: 63